Therapeutics News and Research

RSS

New COLD-PCR technology to detect EGFR gene mutation

Transgenomic, Inc. today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene.

8 Nov 2010

Soy-based drug could prevent prostate cancer metastasis

Northwestern Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University have found that a new, nontoxic drug made from a chemical in soy could prevent the movement of cancer cells from the prostate to the rest of the body.

8 Nov 2010

Mederi's second generation Stretta and Secca Systems granted CE Mark approval

Mederi Therapeutics Inc announced today that it has received a CE Mark authorizing the European distribution and use of Mederi's second generation of the Stretta and Secca Systems. The Stretta System is for treatment of gastric reflux disease, commonly known as GERD, and the Secca System is for treatment of bowel control disorder, or BCD. These latest systems include a streamlined user interface, significant improvements in ease of use, and are smaller, lighter, and highly portable.

8 Nov 2010

Guided Therapeutics receives $244,479 federal grant to advance LightTouch Cervical Scanner

Guided Therapeutics, Inc. announced that it received a $244,479 Federal grant to advance its LightTouch™ Cervical Scanner, currently under FDA review for market approval.

8 Nov 2010

Gents renews distribution agreement for AcnEase with Herborium

Herborium Group, Inc., a Botanical Therapeutics™ company, during its shareholder conference call yesterday afternoon, announced that Gents, AB of Helsingborg, Sweden, renewed its distribution agreement to supply AcnEase® throughout Sweden.

8 Nov 2010

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.

8 Nov 2010

Pervasis receives $920,000 in grants under QTDP program

Pervasis Therapeutics, Inc. today announced that it has been awarded over $920,000 in grants through the U.S. government's Qualifying Therapeutic Discovery Project, which provides tax credits and grants to projects that show significant potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years.

8 Nov 2010

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Jasco Pharmaceuticals, LLC was awarded a grant under the US Government's Patient Protection and Affordable Care Act (PPACA) of 2010. The grant was related to Jasco Pharma's novel small molecule Pim inhibitor program intended to develop therapeutics for the treatment of cancer.

8 Nov 2010

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

4 Nov 2010

Stereotaxis receives $1.5 million in grants under QTDP program

Stereotaxis, Inc. announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

Aestus receives $244,000 grant from QTDP program

Today Aestus Therapeutics, Inc. announced that it has been awarded a $244,000 grant from the U.S. Government's Qualifying Therapeutic Discovery Project program.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

Acceleron receives grants for five projects under QTDP program

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Cardium receives $245,000 grant under QTDP program

Cardium Therapeutics today announced that it was awarded a cash grant of approximately $245,000 under the U.S. Government's Qualifying Therapeutic Discovery Project program to further its Generx clinical development program.

4 Nov 2010

Cocrystal receives $733,438 in grants from QTDP program

Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.

4 Nov 2010

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.

4 Nov 2010

Regulus receives $488,989 grant under QTDP program

Regulus Therapeutics Inc. announced today that it has been awarded two grants totaling $488,989 under the Federal government's Qualifying Therapeutic Discovery Project Program.

4 Nov 2010